|
gptkbp:instanceOf
|
biotechnology company
|
|
gptkbp:acquisition
|
gptkb:Fumapharm_AG
gptkb:Acorda_Therapeutics
gptkb:Syntimmune
gptkb:Zymeworks_Inc.
OncoImmune
Conforma Therapeutics
Alynylam_Pharmaceuticals
Cambridge_Antibody_Technology
Neurimmune_AG
Therapix_Biosciences
|
|
gptkbp:CEO
|
gptkb:Michel_Vounatsos
|
|
gptkbp:clinicalTrials
|
Phase 3 trials
Phase 1 trials
Phase 2 trials
|
|
gptkbp:drugInterdiction
|
biopharmaceuticals
|
|
gptkbp:employees
|
7,000+
|
|
gptkbp:focus
|
Alzheimer's disease
neurodegenerative diseases
multiple sclerosis
neurological diseases
spinal muscular atrophy
|
|
gptkbp:founded
|
1978
|
|
gptkbp:founder
|
M._A._(M._A.)
|
|
gptkbp:headCoach
|
7,500 (2021)
|
|
gptkbp:headquarters
|
gptkb:Cambridge,_Massachusetts
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Biogen Idec MA Inc.
|
|
gptkbp:industry
|
Biotechnology
|
|
gptkbp:location
|
gptkb:Asia
gptkb:North_America
Europe
|
|
gptkbp:market
|
$40 billion (2021)
|
|
gptkbp:partnerships
|
gptkb:Samsung_Bioepis
|
|
gptkbp:products
|
gptkb:Tecfidera
gptkb:Avonex
gptkb:Tysabri
|
|
gptkbp:researchAndDevelopment
|
$2.5 billion (2020)
|
|
gptkbp:revenue
|
$13.45 billion (2020)
|
|
gptkbp:stockSymbol
|
gptkb:BIIB
|
|
gptkbp:subsidiary
|
gptkb:Ionis_Pharmaceuticals
|
|
gptkbp:tradedOn
|
gptkb:NASDAQ
|
|
gptkbp:website
|
www.biogen.com
|